Used primarily in the management of sickle cell disease, this antibody targets P-selectin to reduce the frequency of vaso-occlusive crises. By inhibiting cell adhesion, it helps maintain blood flow and prevents blockage in small vessels. It is administered intravenously and has shown efficacy in reducing pain episodes in patients, especially those unresponsive to other treatments. Its application extends to improving quality of life and reducing hospitalizations related to acute complications of sickle cell disease.